Scientific article
Open access

Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy

Published inArchives of neurology, vol. 63, no. 9, p. 1318-1320
Publication date2006

In several studies, antiretroviral drugs (principally zidovudine) have been used with success in the treatment of myelopathy associated with human T-lymphotrophic virus 1 (HTLV-1) (tropical spastic paraparesis-HTLV-1-associated myelopathy). The retrovirus HTLV-1 has been implicated as a causative agent of Sjögren syndrome (SS) in clinical reports and murine experiments. Moreover, a recognized complication of primary SS is a myelopathy, which has been shown in case reports to respond to immunosuppressive treatment.

  • Adenine/analogs & derivatives/therapeutic use
  • Antiviral Agents/therapeutic use
  • Drug Therapy, Combination
  • Female
  • HTLV-I Infections/complications/drug therapy/radiotherapy
  • Humans
  • Immunosuppressive Agents/therapeutic use
  • Lamivudine/therapeutic use
  • Magnetic Resonance Imaging/methods
  • Methylprednisolone/therapeutic use
  • Middle Aged
  • Organophosphonates/therapeutic use
  • Prednisone/therapeutic use
  • Sjogren's Syndrome/complications/drug therapy/radiography
Citation (ISO format)
POT, Caroline et al. Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy. In: Archives of neurology, 2006, vol. 63, n° 9, p. 1318–1320. doi: 10.1001/archneur.63.9.1318
Main files (1)
Article (Published version)
ISSN of the journal0003-9942

Technical informations

Creation12/09/2014 11:35:00 AM
First validation12/09/2014 11:35:00 AM
Update time03/14/2023 10:35:40 PM
Status update03/14/2023 10:35:40 PM
Last indexation01/16/2024 3:37:06 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack